Administration of RIPK1 inhibitors protected mature oligodendrocytes from death and alleviated symptoms of nerve injury in a mouse model of MS, suggesting that inhibition of RIPK1 activity inhibits demyelination (Yoshikawa et al., 2018; Fan et al., 2019). Here, RIPK1 is linked to myeloid sarcoma.